Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid: synthesis and evaluation of antihepatocellular carcinoma activity.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2011-04-19

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/jm1014814PMID 21504204
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Synthesis and anti-human hepatocellular carcinoma activity of new nitric oxide-releasing glycosyl derivatives of oleanolic acid.

  2010cited by this paper
• Synthesis and evaluation of nitric oxide-releasing derivatives of farnesylthiosalicylic acid as anti-tumor agents.

  2010cited by this paper
• New derivatives of farnesylthiosalicylic acid (salirasib) for cancer treatment: farnesylthiosalicylamide inhibits tumor growth in nude mice models.

  2009cited by this paper
• The Ras inhibitor farnesylthiosalicyclic acid (FTS) prevents nodule formation and development of preneoplastic foci of altered hepatocytes in rats.

  2009cited by this paper
• Design, synthesis, and antihepatocellular carcinoma activity of nitric oxide releasing derivatives of oleanolic acid.

  2008cited by this paper
• Anticancer properties of the novel nitric oxide-donating compound (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid-nitric oxide in vitro and in vivo

  2008cited by this paper
• Novel advancements in the management of hepatocellular carcinoma in 2008.

  2008cited by this paper
• Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors

  2006cited by this paper
• A Ras inhibitor tilts the balance between Rac and Rho and blocks phosphatidylinositol 3-kinase-dependent glioblastoma cell migration.

  2006cited by this paper
• Ubiquitous activation of Ras and Jak/Stat pathways in human HCC.

  2006cited by this paper
• Nitric oxide‐mediated regulation of hypoxia‐induced B16F10 melanoma metastasis

  2004cited by this paper
• Design and synthesis of 3'- and 5'-O-(3-benzenesulfonylfuroxan-4-yl)-2'-deoxyuridines: biological evaluation as hybrid nitric oxide donor-nucleoside anticancer agents.

  2004cited by this paper
• Nitric oxide does not mediate but inhibits transformation and tumor phenotype.

  2003cited by this paper
• Influence of the nitric oxide donor glyceryl trinitrate on apoptotic pathways in human colon cancer cells.

  2002cited by this paper
• Differential Activation of the Rac Pathway by Ha-Ras and K-Ras*

  2001cited by this paper
• Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3'-kinase and distinct from that induced by hypoxia.

  2000cited by this paper
• Nitric oxide (NO): formation and biological roles in mammalian systems.

  1999cited by this paper
• Nitric oxide (NO): formation and biological roles in mammalian systems.

  1999cited by this paper
• Targeting of K-Ras 4B by S-trans,trans-farnesyl thiosalicylic acid.

  1999cited by this paper
• Ras signalling and apoptosis.

  1998cited by this paper
• Dislodgment and accelerated degradation of Ras.

  1998cited by this paper
• Stimulation of Membrane Ruffling and MAP Kinase Activation by Distinct Effectors of RAS

  1996cited by this paper
• Regulation of Epidermal Growth Factor Receptor Signaling by Phosphorylation of the Ras Exchange Factor hSOS1 (*)

  1996cited by this paper
• Selective Inhibition of Ras-dependent Cell Growth by Farnesylthiosalisylic Acid (*)

  1995cited by this paper
• Proteins regulating Ras and its relatives

  1993cited by this paper
• Application of chemical cytochrome P-450 model systems to studies on drug metabolism. IV. Mechanism of piperidine metabolism pathways via an iminium intermediate.

  1991cited by this paper
• Point mutation, allelic loss and increased methylation of c‐Ha‐Ras gene in human hepatocellular carcinoma

  1991cited by this paper
• Characterization of a transforming N-ras gene in the human hepatoma cell line Hep G2: additional evidence for the importance of c-myc and ras cooperation in hepatocarcinogenesis.

  1990cited by this paper
• ras oncogenes in human cancer: a review.

  1989cited by this paper
• The ras gene family and human carcinogenesis.

  1988cited by this paper
• Amino ketone formation and aminopropanol-dehydrogenase activity in rat-liver preparations.

  1967cited by this paper

• Synthesis of self-immolative NO donor-aurovertin B conjugate as potent anti-triple negative breast cancer agents.

  2025cites this paper
• Design, Synthesis, Biological Evaluation, and In Silico Studies of Novel Multitarget Cinnamic Acid Hybrids

  2025cites this paper
• An overview of phenylsulfonylfuroxan-based nitric oxide donors for cancer treatment.

  2024cites this paper
• Discovery of NO Donor-Aurovertin Hybrids as Dual Ferroptosis and Apoptosis Inducers for Treating Triple Negative Breast Cancer.

  2024cites this paper
• Discovery of novel hybrids of mTOR inhibitor and NO donor as potential anti-tumor therapeutics.

  2023cites this paper
• Network Pharmacology Combined with Machine Learning to Reveal the Action Mechanism of Licochalcone Intervention in Liver Cancer

  2023cites this paper
• Design, synthesis and biological evaluation of novel hybrids of quinazoline derivatives and phenylsulfonylfuroxan as potential anti-tumor agents

  2023cites this paper
• Novel nitric oxide-releasing derivatives of pyranocarbazole as antitumor agents: Design, synthesis, biological evaluation, and nitric oxide release studies.

  2022cites this paper
• Design, synthesis and anti-ovarian cancer activities of thieno[2,3-d]pyrimidine based chimeric BRD4 inhibitor/nitric oxide-donator.

  2022cites this paper
• A Tumor‐Specific Platform of Peroxynitrite Triggering Ferroptosis of Cancer Cells

  2022cites this paper
• Synthesis and biological evaluation of novel hybrids of phenylsulfonyl furoxan and phenstatin derivatives as potent anti-tumor agents.

  2022cites this paper
• Novel Hybrids of 3-Substituted Coumarin and Phenylsulfonylfuroxan as Potent Antitumor Agents with Collateral Sensitivity against MCF-7/ADR.

  2022cites this paper
• Development of novel nitric oxide-releasing quinolinedione/furoxan hybrids as NQO1 inhibitors for intervention of drug-resistanthepatocellular cancer.

  2022cites this paper
• Lipophilic Salirasib analogs with enhanced antiproliferative activity against human solid tumor cell lines

  2021cites this paper
• Discovery of β-carboline-(phenylsulfonyl)furoxan hybrids as potential anti-breast cancer agents.

  2021cites this paper
• Self-Assembly Dual-Responsive NO Donor Nanoparticles for Effective Cancer Therapy.

  2021cites this paper
• Nitric oxide-donating and reactive oxygen species-responsive prochelators based on 8-hydroxyquinoline as anticancer agents.

  2021cites this paper
• Design, synthesis, and in vitro evaluation of novel P2X7 antagonists.

  2020cites this paper
• Antiproliferative chromone derivatives induce K562 cell death through endogenous and exogenous pathways

  2020cites this paper
• Novel NO-releasing scopoletin derivatives induce cell death via mitochondrial apoptosis pathway and cell cycle arrest.

  2020cites this paper
• 1,2,5-Oxadiazoles

  2020cites this paper
• NO and hepatocellular cancer

  2019cites this paper
• Synthesis and Antitumor Evaluation of Novel Hybrids of Phenylsulfonylfuroxan and Estradiol Derivatives

  2019cites this paper
• Design, synthesis and anti‐tumor evaluation of novel steroidal glycoconjugate with furoxan derivatives

  2019cites this paper
• Novel Nitric Oxide Donors of Phenylsulfonylfuroxan and 3-Benzyl Coumarin Derivatives as Potent Antitumor Agents.

  2018cites this paper
• Antitumor Effect by Hydroxyapatite Nanospheres: Activation of Mitochondria-Dependent Apoptosis and Negative Regulation of Phosphatidylinositol-3-Kinase/Protein Kinase B Pathway.

  2018cites this paper
• Design, synthesis, and biological evaluation of novel nitric oxide releasing dehydroandrographolide derivatives.

  2018cites this paper
• tert- Butyl Nitrite Mediated Different Functionalizations of Internal Alkenes: Paths to Furoxans and Nitroalkenes

  2018cites this paper
• Discovery of traditional Chinese medicine monomers and their synthetic intermediates, analogs or derivatives for battling P-gp-mediated multi-drug resistance.

  2018cites this paper
• Potent Inhibition of Nitric Oxide-Releasing Bifendate Derivatives against Drug-Resistant K562/A02 Cells in Vitro and in Vivo.

  2017cites this paper
• Nitric oxide-donating derivatives of hederacolchiside A1: Synthesis and biological evaluation in vitro and in vivo as potential anticancer agents.

  2017cites this paper
• Nitric oxide donor hybrid compounds as promising anticancer agents.

  2017cites this paper
• Scutellarin derivatives as apoptosis inducers: Design, synthesis and biological evaluation.

  2017cites this paper
• Molecular Hybridization Tools in the Development of Furoxan‐Based NO‐Donor Prodrugs

  2017cites this paper
• Therapeutic role of nitric oxide as emerging molecule.

  2017cites this paper
• Nitric Oxide Donor-Based Cancer Therapy: Advances and Prospects.

  2017cites this paper
• Novel NO-releasing plumbagin derivatives: Design, synthesis and evaluation of antiproliferative activity.

  2017cites this paper
• Short and efficient synthesis of 1-(2-oxido-1,2,5-oxadiazol-3-yl)alkyl nitrates by unconventional nitrooxylation of 3-alkyl-1,2,5-oxadiazole 2-oxides

  2016cites this paper
• NO-Releasing Enmein-Type Diterpenoid Derivatives with Selective Antiproliferative Activity and Effects on Apoptosis-Related Proteins

  2016cites this paper
• Anticancer efficacy of a nitric oxide‐modified derivative of bifendate against multidrug‐resistant cancer cells

  2016cites this paper
• Synthesis and biological evaluation of nitric oxide-releasing hybrids from gemcitabine and phenylsulfonyl furoxans as anti-tumor agents

  2015cites this paper
• Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor.

  2015cites this paper
• Synthesis and antitumor evaluation of novel hybrids of phenylsulfonylfuroxan and epiandrosterone/dehydroepiandrosterone derivatives.

  2015cites this paper
• Nitric oxide in liver diseases.

  2015cites this paper
• FUROXAN DERIVATIVES AS NITRIC OXIDE DONORS AND THEIR THERAPEUTIC POTENTIAL

  2015cites this paper
• Design, synthesis and biological evaluation of nitro oxide donating N-hydroxycinnamamide derivatives as histone deacetylase inhibitors.

  2014cites this paper
• Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growth factor receptor inhibitors.

  2014cites this paper
• Hybrids of phenylsulfonylfuroxan and coumarin as potent antitumor agents.

  2014cites this paper
• NG as a novel nitric oxide donor induces apoptosis by increasing reactive oxygen species and inhibiting mitochondrial function in MGC803 cells.

  2014cites this paper
• Synthesis and biological evaluation of farnesylthiosalicylamides as potential anti-tumor agents.

  2014cites this paper
• Synthesis and biological evaluation of novel farnesylthiosalicylic acid/salicylic acid hybrids as potential anti-tumor agents

  2014cites this paper
• Identification of Gut Microbial Metabolites of a Synthetic Nitric Oxide-Releasing Farnesylthiosalicylic Acid Derivative, an Antitumor Agent

  2014cites this paper
• Synthesis and Biological Evaluation of Novel Farnesylthiosalicylic Acid Derivatives for Cancer Treatment

  2014cites this paper
• Synthesis and in vitro biological evaluation of nitric oxide-releasing derivatives of hydroxylcinnamic acids as anti-tumor agents

  2013cites this paper
• Nitric oxide donating anilinopyrimidines: synthesis and biological evaluation as EGFR inhibitors.

  2013cites this paper
• Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer.

  2013cites this paper
• Synthesis of novel furozan-based nitric oxide-releasing derivatives of 1-oxo-oridonin with anti-proliferative activity

  2012cites this paper
• Synthesis and in vitro biological evaluation of farnesylthiosalicylic acid derivatives as anti-tumor carcinoma agents

  2012cites this paper
• Nitrogen-rich energetic monoanionic salts of 3,4-bis(1H-5-tetrazolyl)furoxan.

  2012cites this paper
• Synthesis and Biological Evaluation of Novel Furozan-Based Nitric Oxide-Releasing Derivatives of Oridonin as Potential Anti-Tumor Agents

  2012cites this paper
• Synthesis and evaluation of nitric oxide-releasing DDB derivatives as potential Pgp-mediated MDR reversal agents in MCF-7/Adr cells.

  2012cites this paper
• Biological activity of ruthenium nitrosyl complexes.

  2012cites this paper
• Novel nitric oxide-releasing isochroman-4-one derivatives: Synthesis and evaluation of antihypertensive activity.

  2012cites this paper
• Nitrogen‐Rich Energetic Dianionic Salts of 3, 4‐Bis(1H‐5‐­tetrazolyl)furoxan with Excellent Thermal Stability

  2012cites this paper